Description
Semaglutide is a synthetic GLP-1 analog research peptide with a C18 fatty-diacid modification. It is supplied as a high-purity lyophilized powder for laboratory use only.
The compound is a modified 31-amino-acid analog of glucagon-like peptide-1. Reported specifications commonly include a molecular weight of approximately 4114 g/mol. Identity and purity are confirmed by HPLC and mass spectrometry.
In laboratory and preclinical research, semaglutide has been investigated for effects on GLP-1 receptor signaling, including studies related to incretin-pathway activity, glycemic-regulation models, and energy-balance mechanisms in experimental systems. These findings are limited to research settings and do not establish approved medical use.
This material is not approved for human or veterinary use and is not intended for consumption.
Reviews
There are no reviews yet.